Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Authors:
- 15 March 2024
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 23 (5) , 465-476
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gelBrain and Behavior, 2021
- Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND StudyMovement Disorders, 2021
- Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized TrialMovement Disorders, 2021
- Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐AnalysisMovement Disorders, 2021
- International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's diseaseMovement Disorders, 2018
- Levodopa: A new look at an old friendMovement Disorders, 2017
- Questionnaire for impulsive‐compulsive disorders in Parkinson's Disease–Rating ScaleMovement Disorders, 2011
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing resultsMovement Disorders, 2008
- Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challengesMovement Disorders, 2004